Lundbeck to acquire Abide TherapeuticsAcquisitions, Business, Central Nervous System Diseases, Enzymes, Serine hydrolase inhibitors, Tourette syndromeThe acquisition of Abide Therapeutics Inc. will provide H. Lundbeck A/S with a unique discovery platform and a lead compound in an exploratory phase IIa program for Tourette’s syndrome. Read more May 6, 2019/by GlobeNewswire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 GlobeNewswire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png GlobeNewswire2019-05-06 01:27:272019-05-06 13:17:58Lundbeck to acquire Abide Therapeutics